咪喹莫特预处理联合皮内乙肝疫苗用于透析患者
第52周,咪喹莫特+皮内组的血清保护率为96.9%,显著高于后两组的74.2%和48.4%(P<.0001)。结论认为该方案安全且血清保护效果良好。
要点
- 咪喹莫特预处理后皮内接种乙肝疫苗可显著提高透析患者第52周血清保护率
- 该组第52周几何平均浓度为1135 mIU/mL,高于两个对照组
- 不良反应少见,咪喹莫特+皮内接种是唯一独立预测因素
核心结论
- 透析患者接种乙肝疫苗前局部使用TLR7激动剂咪喹莫特,可安全地获得良好的血清保护。
主要发现
- 第52周血清保护率:咪喹莫特+皮内组96.9%,安慰剂+皮内组74.2%,安慰剂+肌内组48.4%(P<.0001)。
- 第52周几何平均浓度:咪喹莫特+皮内组1135(95%CI 579.4-2218.2)mIU/mL,安慰剂+皮内组86.9(95%CI 18.5-409.3)mIU/mL,安慰剂+肌内组7.2(2.0-26.5)mIU/mL(P<.0001)。
- 咪喹莫特+皮内接种是唯一与更高52周血清保护率独立相关的因素(OR 3.70,95%CI 1.16-11.81;P=.027)。
- 不良反应少见。
关键数值与推荐
- 入组患者中57.4%为既往无应答者;主要终点为第52周乙肝表面抗体≥10 mIU/mL的血清保护率。
临床怎么用
- 对透析患者可考虑在皮内接种Sci-B-Vac前局部预处理咪喹莫特,以提高血清保护率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients on dialysis are hyporesponsive to the hepatitis B virus vaccines (HBVv). We examined intradermal (ID) HBVv Sci-B-Vac, with topical Toll-like receptor 7 (TLR7) agonist imiquimod pretreatment in dialysis patients. METHODS: We enrolled and prospectively followed adult patients on dialysis between January 2016 and September 2018. Eligible patients were randomly allocated (1:1:1) into 1 treatment group, topical imiquimod cream followed by ID HBVv (IMQ + ID); and 2 control groups: topical aqueous cream (placebo) followed by ID HBVv (AQ + ID) or topical aqueous cream followed by intramuscular HBVv (AQ + IM). The primary endpoint was the seroprotection rate (hepatitis B surface antibody ≥10 mIU/mL) at 52 weeks. RESULTS: Ninety-four patients were enrolled, among which 57.4% were previous nonresponders. Seroprotection rate was significantly better at week 52 for the IMQ + ID group with 96.9% compared to 74.2% and 48.4% for AQ + ID and AQ + IM groups, respectively (P < .0001). The geometric mean concentration was significantly higher at week 52 for the IMQ + ID group: 1135 (95% confidence interval [CI], 579.4-2218.2) mIU/mL, compared to 86.9 (95% CI, 18.5-409.3) mIU/mL and 7.2 (2.0-26.5) mIU/mL for the AQ + ID and AQ + IM groups, respectively (P < .0001). IMQ + ID vaccination (odds ratio, 3.70 [95% CI, 1.16-11.81]; P = .027) was the only factor independently associated with higher 52-week seroprotection rate. Adverse reaction was infrequent. CONCLUSIONS: Pretreatment with topical imiquimod before ID HBVv Sci-B-Vac was safe with favorable seroprotection in dialysis patients. CLINICAL TRIALS REGISTRATION: NCT02621112.
引用
- Hung IF, Yap DY, Yip TP, et al. A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis. Clin Infect Dis. 2021. PMID: 32556176. doi:10.1093/cid/ciaa804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。